Autopsy report · NCT04907968

Study of Upifitamab Rilsodotin in Combination With Carboplatin in Participants With High-grade Serous Ovarian Cancer

“Study Terminated by Sponsor”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 2 years 4 months before it stopped.
• 31 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Mersana Therapeutics

Sponsor type

Industry

Conditions

Platinum-sensitive Ovarian Cancer (UPGRADE-A)

Interventions

XMT-1536 (Upifitamab Rilsodotin); Carboplatin

Participants

31

Sites

1

Countries

United States

Trials that died the same way

• Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Liver Transplant Patients
  “Study terminated by the Sponsor” (99% match in meaning)
• Ritlecitinib (PF-06651600) in Participants With Chronic Spontaneous Urticaria
  “Sponsor terminated study” (97% match in meaning)
• Org 24448 (Ampakine) for Cognitive Deficits in Schizophrenia
  “Study terminated at Sponsor's request.” (95% match in meaning)
• Comprehensive Medication Monitoring on Heart Failure Patient Outcomes
  “Study terminated by sponsor for commercial reasons” (95% match in meaning)
• A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 12 Weeks in Adults With Active Primary Sjögren's Syndrome (pSS)
  “Study was terminated based on Sponsor decision” (94% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.